Tenax Therapeutics, Inc. TENX · Stock Open Tenax Therapeutics, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Tenax Therapeutics, Inc. Analysis (TENX)
Is Tenax Therapeutics, Inc. a good investment? Tenax Therapeutics, Inc. (TENX) is currently trading at 1.81 USD. Market analysts have a consensus price target of 9.63 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 2.41. This relatively low multiple may signal that Tenax Therapeutics, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Tenax Therapeutics, Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -1.50.
Investor FAQ
Does Tenax Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Tenax Therapeutics, Inc.?
Tenax Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -1.48.
Company Profile
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 9, 2009 | 0.07 |
| May 13, 2013 | 1:20 |
| Feb. 26, 2018 | 1:20 |
| Jan. 5, 2023 | 1:20 |
| Jan. 3, 2024 | 1:100 |
Community Discussion